E ven in patients who achieve return of spontaneous circulation (ROSC), survival to hospital discharge after sudden cardiac arrest has been reported to range from 5% to 40% (1, 2) . Given such poor outcomes likely depend on the neurological insult incurred during the arrest, recent focus has turned to potential interventions aimed at improving postarrest neurological function and, ultimately, mortality. Mild therapeutic hypothermia (TH) has been shown in a number of studies to improve neurological outcomes, decrease mortality (3, 4) , and is now recommended for patients having suffered an out-of-hospital cardiac arrest from a ventricular arrhythmia (5, 6) . Because TH may modulate the systemic inflammatory response seen after cardiac arrest (7) , its use in clinical practice has been extended to patients after cardiac arrest from nonventricular arrhythmias, such as asystole and pulseless electrical activity.
Hyperoxia may play a role in the pathogenesis of the postcardiac arrest syndrome (8) and is a potentially modifiable risk factor for poor neurological outcomes and death in patients who achieve ROSC (9) . The pathophysiologic mechanisms underlying these poor outcomes are unclear, but some evidence suggests increased formation of reactive oxygen species resulting in lipid peroxidation of neuronal cells (10) (11) (12) , impairment in cerebral oxidative energy metabolism (13) , and cerebral and myocardial vasoconstriction in the setting of increased arterial oxygen tension (14, 15) . TH is also thought to have protective effects against damaging reactive oxygen species (16, 17) ; however, it is unknown if hyperoxia is associated with mortality or poor neurological outcomes in patients undergoing TH.
We conducted a retrospective analysis of a prospective cohort to test the hypothesis that increasing levels of the maximum measured Pao 2 in the first 24 hrs after sudden cardiac arrest are associated with an increased risk of in-hospital mortality and poor neurological outcome in patients treated with TH.
MATERIALS AND METHODS
Study Design. The study population included 173 consecutive comatose patients who were treated with mild TH following sudden cardiac arrest at Vanderbilt University Medical Center between May 15, 2007 , and January 2, 2012. Patients determined by their treating physician to be suitable for mild TH were externally cooled to maintain a target temperature of 32-34°C for 24 hrs following ROSC, after which they were rewarmed passively at a rate of 0.25°C per hour. After approval from the institutional review board, data were collected prospectively on these patients, including initial rhythm, time to ROSC, receipt of Objective: To determine whether higher levels of Pao 2 are associated with in-hospital mortality and poor neurological status at hospital discharge in patients treated with mild therapeutic hypothermia after sudden cardiac arrest.
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For information regarding this article, E-mail: david. janz@vanderbilt.edu bystander cardiopulmonary resuscitation, Cerebral Performance Category (CPC) score at hospital discharge, and hospital mortality. We returned to these patients' records and retrospectively collected the highest measured Pao 2 in the first 24 hrs following cardiac arrest.
The primary analysis for this study was inhospital mortality. The secondary analysis was poor neurological outcome defined as a CPC score of ≥3. The CPC score was developed as a measure of central nervous system function after cardiac arrest and has become the most commonly used outcome tool for this purpose (3, 4, 18) . A CPC score between 3 and 5 has been recommended for use as defining a poor neurological outcome in study patients and clinically represents a range of neurological function from no neurological disability to death (18) .
Inclusion/Exclusion Criteria. All patients treated with TH and who also had at least one Pao 2 measured in the first 24 hrs following cardiac arrest were included. This time period was chosen because it covers the time of active cooling in TH. Patients without a Pao 2 measured in the first 24 hrs following cardiac arrest were excluded.
Statistical Analysis. Univariable analyses were conducted using Wilcoxon's rank sum test for continuous variables, Fisher's exact test, and chi-square for a trend tests for categorical variables, and Kruskal-Wallis test for ordinal variables. Median values with interquartiles were used for continuous variables and frequencies for categorical variables. Multivariable logistic regression models were developed for the outcomes of in-hospital mortality and poor neurological outcome; explanatory variables included known risk factors for poor outcomes in this patient population and those selected using data reduction methods. Pertinent variables with p ≤ .10 in univariable analyses were included in the final multivariable regression model. In addition, shock, as defined by the requirement of vasoactive medications to maintain a mean arterial blood pressure ≥65 mm Hg, was determined a priori to be an important potential confounder and included in the regression model. IBM SPSS Statistics (SPSS, Inc, Chicago, IL) was used for statistical analysis; a two-sided significance level of .05 was used for statistical inference.
RESULTS
Clinical Characteristics. Of the 173 patients considered for inclusion, 170 had at least one Pao 2 measured in the first 24 hrs following cardiac arrest and, therefore, defined the study population. All Pao 2 measurements included in the analysis were obtained while patients were at the target temperature of 32-34°C. Table 1 displays a comparison of baseline characteristics. Overall, survivors were younger, were more likely to have had a ventricular arrhythmia as the cause of their arrest, had shorter ROSC time, and had a lower median Pao 2 . There was no significant difference in gender, the presence of shock requiring vasoactive medications, number of patients who received bystander cardiopulmonary resuscitation, or the number of hours spent at the target TH temperature. The median highest Pao 2 among all patients was 226.5 mm Hg (interquartile range [IQR] 162.7-309) with a range from 54 mm Hg to 608 mm Hg (Fig. 1A and B) .
Mortality. Of the 170 patients included in the final analysis, 93 (54.7%) died during hospitalization. Survivors had a significantly lower maximum Pao 2 (198 mm Hg; IQR 152.5-282) measured in the first 24 hrs following cardiac arrest compared to nonsurvivors (254 mm Hg; IQR 172-363; p = .022; Fig. 2) .
Using data reduction methods and accounting for known risk factors for in-hospital mortality, a multivariable logistic regression model was developed to examine the association between highest measured Pao 2 and mortality. After controlling for age, time to ROSC, presence of shock, bystander cardiopulmonary resuscitation, and initial rhythm, higher levels of Pao 2 were significantly associated with an increased risk of inhospital mortality (odds ratio 1.439; 95% confidence interval 1.028-2.015; p = .034; Table 2 ; Fig. 3 ). Poor Neurological Outcome. Of the 170 patients in the final analysis, 100 (58.8%) had a poor neurological outcome on hospital discharge, defined as a CPC ≥3. Patients with favorable neurological outcomes (CPC score of 1 or 2) had a significantly lower maximum Pao 2 (197 mm Hg; IQR 151.5-288.7) measured in the first 24 hrs following cardiac arrest compared to patients with poor neurological outcomes (246.5 mm Hg; IQR 172-357; p = .026; Fig. 4 ). After controlling for the same variables used in the mortality analysis, there was a significant association between higher levels of Pao 2 and poor neurological outcome at hospital discharge (odds ratio 1.485; 95% confidence interval 1.032-2.136; p = .033; Table 3 ).
In an effort to determine whether there is a threshold Pao 2 level at which the CPC score significantly worsens, maximum Pao 2 levels in the first 24 hrs after cardiac arrest were divided into quartiles and CPC scores in each quartile were compared. Overall, there was no statistically significant association between increasing Pao 2 and a change in CPC score (p = .08); however, there were significant differences in CPC score between the first Pao 2 quartile (54-163 mm Hg) and second Pao 2 quartile (164-227 mm Hg) compared to the fourth quartile (310-608 mm Hg; p = .038 and .018, respectively; Fig. 5 ).
DISCUSSION
In this retrospective analysis of a prospective cohort, there was a significant association between the maximum Pao 2 measured, in-hospital mortality, and poor neurological status on hospital discharge in victims of sudden cardiac arrest undergoing TH. These findings are similar to associations found in previous studies of patients with out-of-hospital cardiac arrest (9, 19) , chronic obstructive pulmonary disease (20, 21) , and acute myocardial infarction (22) .
It is unclear which specific effects of hyperoxia result in poor neurological outcomes and mortality. One proposed mechanism is the hyperoxia-induced increase in the generation of ROS and their subsequent peroxidation of neuronal lipid membranes (11) (12) . To our knowledge, this study is the first to examine the effects of increasing Pao 2 levels in patients undergoing TH and demonstrates an association between hyperoxia and worse outcomes in this population (19) . Our study is unable to answer whether TH may still provide some protection against the oxidative effects of hyperoxia or whether there is a threshold Pao 2 above which exposure is more deleterious. In addition, we chose to account for the maximum Pao 2 measured in the first 24 hrs after cardiac arrest rather than using the first Pao 2 measured because hyperoxia at any time point during TH should, theoretically, be harmful to patients and deleterious to the benefit of 24 hrs of TH. This study is also unique, in that we chose to analyze Pao 2 as a continuous variable rather than dividing groups into hyperoxia and normoxia, adding strength to our statistical findings and biologic plausibility to our hypothesis. Hyperoxia has been shown to cause vasoconstriction (14, 15) , potentially severe enough to actually reduce overall oxygen delivery to vital tissues such as the heart and brain, even despite supratherapeutic arterial oxygen concentrations. Although not addressed in our study, if the deleterious effects of hyperoxia are mediated via a mechanism other than ROS, such as vasoconstriction, it is not surprising that TH may fail to lessen these effects.
Our study has a number of limitations. First, this is a retrospective analysis of a prospectively collected, observational cohort that only allows us to suggest associations rather than causation. Noninvasive measurement of arterial oxygen saturation is inaccurate in the setting of hypotension and can be associated with the practitioner's response of increasing the inspired oxygen, creating a situation where hyperoxia is a marker of shock rather than a true risk for poor outcomes. It is difficult to account for this aspect of bedside management in this analysis; however, there was no difference in the prevalence of shock between groups and shock was not significantly associated with either mortality or poor neurological outcome in multivariable analysis, while maximum Pao 2 remained significantly associated with both. Because acute physiology and chronic health evaluation scores have not been validated and may be inaccurate in cardiac arrest and TH populations (23) and have not been used in previous landmark studies (3, 4, 24-26), we chose not to control for acute physiology and chronic health evaluation score in our regression model. We tried to control for severity of illness by including shock in our model. However, omission of a more conventional severity of illness score such as acute physiology and chronic health evaluation allows the possibility The odds ratio for maximum Pao 2 is for an increment of every 100 mm Hg above 54 mm Hg.
that patients who were more ill were also more likely to receive higher Fio 2 . We did not have data on the Fio 2 administered at the time of blood gas analysis to control for this additional, potential confounder. Finally, our analysis prohibits commentary on whether the associated outcomes are a result of one elevated Pao 2 level or whether the underlying pathogenesis involves a dose-response relationship.
Our results differ from a recent, large cohort study that found the association between hyperoxia and worse mortality was lost in multivariable analysis when severity of illness was included in the regression model (27) . However, that study used worst alveolar-arterial gradient and not Pao 2 . Alveolar-arterial gradient does not correlate in a linear fashion with the Pao 2 as Fio 2 increases (28, 29) . Furthermore, the oxygen levels in their cohort were considerably lower than the hyperoxia seen in our and other studies. The mean Pao 2 in their study was 112 mm Hg compared to 248 mm Hg in our study, and the lowest end of their highest quartile of Pao 2 starts around 187 mm Hg whereas ours starts at 363 mm Hg.
The implications of these findings are significant for the care of patients and generation of future research. First, hyperoxia is a potentially cost-free, modifiable risk factor that, in this analysis, seems to be detrimental to a therapy (TH) that is not only used to improve outcomes (3, 4) but is also expensive and labor-intensive (30) . The avoidance of hyperoxia after cardiac arrest promises to be a simple and attractive strategy in achieving better outcomes in patients treated with TH. Although current guidelines recommend the use of 100% inspired oxygen during resuscitation (31), normoxic resuscitation or rapid titration of inspired oxygen after ROSC to a goal Pao 2 of normoxia promises improvement in neurological outcomes (12, 32) , and warrant study in humans. Any future therapeutic interventions must also be weighed against the fact that hypoxia is clearly harmful in all patient populations and must be avoided. As our study is in agreement with past investigations (9) , suggesting that the potential harm generated with exposure to increasing levels of Pao 2 occurs above a level of 300 mm Hg, it seems prudent and safe to avoid these high levels and, if encountered, to act with a sense of urgency to return the patient to normoxia.
CONCLUSIONS
Sudden cardiac arrest is associated with high hospital mortality and poor neurological outcomes. Hyperoxia in the postarrest setting is also a risk for the same outcomes. We found that with The odds ratio for maximum Pao 2 is for an increment of every 100 mm Hg above 54 mm Hg. Poor neurological status is defined as Cerebral Performance Category ≥3. There was no statistically significant association between increasing Pao 2 and a change in CPC score (p = .08); however, quartiles 1 and 2 had significantly better CPC scores at discharge than quartile 4 (p = .038* and .018**, respectively). Values are means (middle long horizontal line) and standard deviations (sd: upper and lower caps).
increasing levels of the maximum Pao 2 measured in the first 24 hrs following cardiac arrest, there is an association with increased hospital mortality and poor neurological status on hospital discharge. Given the growing evidence suggesting the harm of hyperoxia and now the potential deleterious effects hyperoxia may have on the benefits of TH, large, randomized, controlled trials should be undertaken to confirm these findings. In addition, more specific oxygenation goals are needed in the postresuscitation care of victims of sudden cardiac arrest.
